Literature DB >> 22233251

In vitro sensitization of T cells with DC-associated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppression.

Swarali Kurle1, Madhuri Thakar, Ashwini Shete, Ramesh Paranjape.   

Abstract

The absence of a suitable animal model for HIV infection is one of the major obstacles to the development of a preventive HIV vaccine. Vaccines showing good response in animal studies may fail in human efficacy trials. We have demonstrated DC-mediated in vitro sensitization of autologous T cells against three HIV constructs. The in vitro sensitized T cells were able to demonstrate a polyfunctional T-cell response, as well as central and effector memory T cells, and virus lysis in a virus inhibition assay, three potentially protective responses. However, none of the constructs could induce all three responses. Also there were variations from volunteer to volunteer. These may be due to genetic and other factors. This study provides evidence of an in vitro system that can be used to assess the immune response against a candidate vaccine, and may also provide the opportunity to modify vaccine constructs to achieve the goal of developing an ideal vaccine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233251      PMCID: PMC3271377          DOI: 10.1089/vim.2011.0055

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  54 in total

Review 1.  Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells.

Authors:  A Lanzavecchia; F Sallusto
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

Review 2.  Exploring pathways for memory T cell generation.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 3.  T-cell quality in memory and protection: implications for vaccine design.

Authors:  Robert A Seder; Patricia A Darrah; Mario Roederer
Journal:  Nat Rev Immunol       Date:  2008-03-07       Impact factor: 53.106

4.  AIDS research. Did Merck's failed HIV vaccine cause harm?

Authors:  Jon Cohen
Journal:  Science       Date:  2007-11-16       Impact factor: 47.728

5.  Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells.

Authors:  J Lisziewicz; D I Gabrilovich; G Varga; J Xu; P D Greenberg; S K Arya; M Bosch; J P Behr; F Lori
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells.

Authors:  S Heinzel; D Rea; R Offringa; G Pawelec
Journal:  Cancer Immunol Immunother       Date:  2001-02       Impact factor: 6.968

7.  Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons.

Authors:  Steven R Fauce; Otto O Yang; Rita B Effros
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

8.  Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.

Authors:  Wenjing Li; Shirui Li; Yu Hu; Bixia Tang; Lianxian Cui; Wei He
Journal:  Vaccine       Date:  2008-04-18       Impact factor: 3.641

9.  Development of a whole blood intracellular cytokine staining assay for mapping CD4(+) and CD8(+) T-cell responses across the HIV-1 genome.

Authors:  Stephen Meddows-Taylor; Sharon Shalekoff; Louise Kuhn; Glenda E Gray; Caroline T Tiemessen
Journal:  J Virol Methods       Date:  2007-05-31       Impact factor: 2.014

10.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Authors:  Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Heeney; Marie-Joelle Frachette; James Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  2 in total

1.  Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.

Authors:  Bernard J C Macatangay; Sharon A Riddler; Nicole D Wheeler; Jonathan Spindler; Mariam Lawani; Feiyu Hong; Mary J Buffo; Theresa L Whiteside; Mary F Kearney; John W Mellors; Charles R Rinaldo
Journal:  J Infect Dis       Date:  2015-12-08       Impact factor: 5.226

2.  Human dendritic cell targeting peptide can be targeted to porcine dendritic cells to improve antigen capture efficiency to stimulate stronger immune response.

Authors:  Tian Xia; Huizhu Yang; Yuyao Guo; Tiantian Guo; Lingxiang Xin; Yanping Jiang; Wen Cui; Han Zhou; Xinyuan Qiao; Xiaona Wang; Jiaxuan Li; Zhifu Shan; Lijie Tang; Li Wang; Yijing Li
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.